Equities Analysts Offer Predictions for Cryoport Q2 Earnings

Cryoport, Inc. (NASDAQ:CYRX - Free Report) - Equities researchers at Roth Capital lifted their Q2 2025 earnings per share (EPS) estimates for Cryoport in a note issued to investors on Thursday, May 8th. Roth Capital analyst R. Baldry now forecasts that the company will earn ($0.26) per share for the quarter, up from their prior estimate of ($0.30). The consensus estimate for Cryoport's current full-year earnings is ($0.99) per share. Roth Capital also issued estimates for Cryoport's Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.96) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.83) EPS.

Cryoport (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The firm had revenue of $41.04 million for the quarter, compared to analysts' expectations of $56.19 million.

CYRX has been the topic of a number of other reports. Roth Mkm restated a "buy" rating and set a $15.00 price target on shares of Cryoport in a research note on Tuesday, April 1st. Guggenheim restated a "buy" rating and set a $10.00 price target on shares of Cryoport in a research note on Wednesday, April 16th. Needham & Company LLC restated a "buy" rating and set a $11.00 price target on shares of Cryoport in a research note on Thursday, May 8th. UBS Group upped their price target on Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st. Finally, Morgan Stanley decreased their price target on Cryoport from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $11.00.

Cryoport Trading Up 2.0%

CYRX traded up $0.13 during trading hours on Monday, reaching $6.86. The company's stock had a trading volume of 98,993 shares, compared to its average volume of 541,156. Cryoport has a fifty-two week low of $4.58 and a fifty-two week high of $14.20. The stock has a market cap of $344.14 million, a PE ratio of -2.04 and a beta of 1.92. The business's 50-day moving average is $5.95 and its 200-day moving average is $6.86. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32.

Institutional Trading of Cryoport

Hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. raised its stake in shares of Cryoport by 148.7% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock valued at $28,000 after acquiring an additional 2,120 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Cryoport in the fourth quarter valued at $51,000. Avanza Fonder AB purchased a new position in Cryoport in the fourth quarter valued at $64,000. SBI Securities Co. Ltd. increased its holdings in Cryoport by 548,750.0% in the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock valued at $67,000 after buying an additional 10,975 shares during the last quarter. Finally, Quarry LP purchased a new position in Cryoport in the fourth quarter valued at $69,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the sale, the chief executive officer now directly owns 765,399 shares in the company, valued at approximately $4,814,359.71. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 19,830 shares of company stock worth $118,353. Corporate insiders own 10.00% of the company's stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.